Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 41,900 shares, a growth of 23.6% from the November 30th total of 33,900 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average trading volume of 14,000 shares, the short-interest ratio is presently 3.0 days.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $9.00 price target on shares of Prenetics Global in a research note on Wednesday, December 4th.

Prenetics Global Stock Down 0.5 %

Shares of PRE stock traded down $0.03 during trading hours on Tuesday, reaching $5.80. 10,471 shares of the stock traded hands, compared to its average volume of 47,859. The business has a fifty day moving average price of $4.90 and a 200 day moving average price of $5.11. Prenetics Global has a 1-year low of $2.85 and a 1-year high of $7.84. The firm has a market capitalization of $52.99 million, a PE ratio of -1.45 and a beta of -0.18.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Monday, October 7th. The company reported ($0.88) earnings per share (EPS) for the quarter. The firm had revenue of $5.94 million for the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. Research analysts expect that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.